ABBN.SW: $86.10 ▼ -2.46 (-2.78%)ASML.AS: $1,560.80 ▼ -95.00 (-5.74%)ENR.DE: $162.50 ▼ -6.64 (-3.93%)GLEN.L: $537.60 ▲ 2.30 (0.43%)IFX.DE: $80.56 ▼ -5.38 (-6.26%)NOKIA.HE: $12.14 ▲ 0.14 (1.13%)RIO.L: $7,280.00 ▲ 16.00 (0.22%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

PainReform Ltd.

PRFX - NASDAQ

Identifiants & Marche

Ticker PRFX
ISIN IL0011651580
CIK 0001801834
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare

Entreprise

Pays IL
Siege N/A
Fondee N/A
Site Web Lien

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.